Drug Profile
SYNT 003
Alternative Names: SYNT003Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Syntimmune
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Cancer in USA
- 02 Nov 2018 Syntimmune has been acquired by Alexion Pharmaceuticals
- 22 Mar 2016 Early research in Cancer in USA (unspecified route)